
|Articles|January 6, 2005
FDA approves new oral agent for overactive bladder
The FDA has approved extended-release darifenacin (Enablex, 7.5 mg and 15 mg) for the treatment of overactive bladder.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
NDV-01 produces robust 9-month results in high-risk NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5


















